Cozad Asset Management Inc. Has $622,000 Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Cozad Asset Management Inc. trimmed its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 7.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,552 shares of the medical instruments supplier’s stock after selling 200 shares during the quarter. Cozad Asset Management Inc.’s holdings in Becton, Dickinson and Company were worth $622,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Jeppson Wealth Management LLC boosted its stake in Becton, Dickinson and Company by 4.0% in the 3rd quarter. Jeppson Wealth Management LLC now owns 1,028 shares of the medical instruments supplier’s stock worth $266,000 after purchasing an additional 40 shares during the period. Value Partners Investments Inc. lifted its holdings in shares of Becton, Dickinson and Company by 5.2% in the third quarter. Value Partners Investments Inc. now owns 867 shares of the medical instruments supplier’s stock valued at $225,000 after purchasing an additional 43 shares in the last quarter. Dover Advisors LLC boosted its position in shares of Becton, Dickinson and Company by 1.7% during the third quarter. Dover Advisors LLC now owns 2,702 shares of the medical instruments supplier’s stock worth $699,000 after buying an additional 45 shares during the period. Mendel Money Management grew its holdings in shares of Becton, Dickinson and Company by 3.0% during the third quarter. Mendel Money Management now owns 1,536 shares of the medical instruments supplier’s stock worth $397,000 after buying an additional 45 shares in the last quarter. Finally, Phillips Wealth Planners LLC raised its position in Becton, Dickinson and Company by 6.0% in the 3rd quarter. Phillips Wealth Planners LLC now owns 818 shares of the medical instruments supplier’s stock valued at $211,000 after buying an additional 46 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Insider Activity

In related news, EVP Michael David Garrison sold 1,715 shares of the stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total value of $399,269.15. Following the sale, the executive vice president now owns 5,381 shares in the company, valued at approximately $1,252,750.61. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, EVP Michael David Garrison sold 1,715 shares of Becton, Dickinson and Company stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the sale, the executive vice president now owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Thomas J. Spoerel sold 282 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total value of $67,197.78. Following the sale, the senior vice president now owns 2,276 shares of the company’s stock, valued at approximately $542,348.04. The disclosure for this sale can be found here. Insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.3 %

NYSE BDX opened at $233.81 on Thursday. Becton, Dickinson and Company has a 12 month low of $229.40 and a 12 month high of $287.32. The company has a current ratio of 1.08, a quick ratio of 0.64 and a debt-to-equity ratio of 0.56. The stock has a 50 day moving average of $238.75 and a 200-day moving average of $240.71. The company has a market cap of $67.55 billion, a PE ratio of 55.41, a PEG ratio of 1.93 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 EPS for the quarter, beating analysts’ consensus estimates of $2.39 by $0.29. The firm had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.73 billion. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter last year, the company posted $2.98 earnings per share. On average, equities research analysts anticipate that Becton, Dickinson and Company will post 12.94 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Monday, June 10th will be paid a $0.95 dividend. The ex-dividend date of this dividend is Monday, June 10th. This represents a $3.80 annualized dividend and a yield of 1.63%. Becton, Dickinson and Company’s dividend payout ratio is 90.05%.

Analysts Set New Price Targets

A number of research firms have weighed in on BDX. Raymond James upped their price target on Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Barclays increased their target price on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a report on Monday, February 5th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $280.00.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.